According to the latest documents submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Bioxytran, Inc. has achieved positive safety data in its clinical research process.

The document clearly states that no reports of serious adverse events occurred during the trial, and all participants completed the prescribed treatment regimen without any interruptions due to treatment-related reasons. This outcome highlights the tolerability of the company's investigational therapy, providing key safety evidence for subsequent clinical advancement. In the current biotech landscape, where drug safety is highly scrutinized, such data undoubtedly strengthens investors' confidence in the research and development process.